Form 4: Apellis Pharmaceuticals General Counsel, David O. Watson, Reports Stock Transactions

David O. Watson, General Counsel of Apellis Pharmaceuticals, reported the sale of 2,201 shares and the acquisition of 42,762 shares through a restricted stock unit award.

Summary

• David O. Watson, General Counsel of Apellis Pharmaceuticals, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On January 17, 2025, Mr. Watson sold 2,201 shares of common stock at a price of $29.9582 per share to cover tax withholding related to restricted stock units.
• On January 21, 2025, Mr. Watson acquired 42,762 shares of common stock through a restricted stock unit award, which vests 25% annually over four years.
• Mr. Watson also has indirect ownership of shares through a custodial account for his son (3,333 shares), The David O. Watson Irrevocable Trust of 2023 (70,136 shares), and The Watson Education Trust (6,667 shares).
• Mr. Watson disclaims beneficial ownership of shares held by the trusts except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions. The stock sale is offset by the larger stock grant, resulting in a neutral to slightly positive sentiment.

Positives

• The acquisition of 42,762 shares through a restricted stock unit award indicates a long-term commitment by Mr. Watson to the company.
• The vesting schedule of the restricted stock units encourages continued service over the next four years.

Negatives

• The sale of 2,201 shares, while for tax purposes, could be perceived negatively by some investors.

Risks

• The sale of shares by an executive, even for tax purposes, could potentially create short-term negative sentiment in the market.
• The vesting schedule of the restricted stock units is subject to continued service, which could be a risk if Mr. Watson were to leave the company.

Future Outlook

The restricted stock units will vest 25% annually over four years from the grant date, subject to continued service.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry. It provides transparency into the ownership changes of key personnel.

Comparison to Industry Standards

• Stock transactions by executives are a common occurrence in publicly traded companies, including those in the pharmaceutical sector.
• The vesting schedule of the restricted stock units is a standard practice for incentivizing long-term commitment from employees.
• The use of trusts for holding shares is also a common practice for estate planning and tax purposes.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholder sentiment, but the overall impact is likely to be minimal.
• The vesting schedule of the restricted stock units incentivizes Mr. Watson to remain with the company, which is beneficial for the company's stability.

Key Dates

Keywords

Apellis Pharmaceuticals, David O. Watson, Form 4, stock transaction, restricted stock units, beneficial ownership, insider trading, General Counsel